



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-Genome polyprotein [14B10] Bulk Size Ab04404-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Human IgG1, Fc Silent™, Kappa

**Clone Number:** 14B10

**Alternative Name(s) of Target:** P1; 18A7

**UniProt Accession Number of Target Protein:** Q9QF31

**Published Application(s):** in vitro, neutralization, ELISA

**Published Species Reactivity:** Coxsackievirus A16

**Immunogen:** The original antibody was raised by immunizing a mouse with CVA16.

**Specificity:** This antibody is specific for the threefold plateau of the canyon of CVA16.

**Application Notes:** The original antibody was used for a neutralization assay against CVA16 in human rhabdomyosarcoma. Further an ELISA was performed on 16 strains of CVA16. The structure of this antibody was determined using cryo-EM (He et al., 2020; PMID:32027857).

**Antibody First Published in:** He et al. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16 Cell Host Microbe. 2020 Feb 12;27(2):249-261. [PMID:32027857](#)

**Note on publication:** The original paper identifies three CVA16-specific neutralizing monoclonal antibodies (nAbs) with therapeutic potential: 18A7, 14B10, and NA9D7.

## Product Form

**Size:** 1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic

procedures for humans or animals.